Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to submit earnings per share (EPS) of $0.93 for the very first quarter of 2021.

The current opinion among 11 TipRanks analysts is for a moderate Buy rating of shares in CVS Health, with an average price target of $84.

The analysts price targets range from a high of hundred one dolars to a low of $61.

In the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.

Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is now ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The retail or Long Term Care segment includes selling of prescribed drugs and assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products and related services, including medical, pharmacy, dental, behavioural health, healthcare management capabilities. The Corporate segment involves in offering administrative services as well as management. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *